This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Cyclin-dependent kinase 1 | |
|---|---|
| Name | CDK1 |
| Uniprot | P06493 |
| Organism | Homo sapiens |
Cyclin-dependent kinase 1 is a highly conserved serine/threonine protein kinase central to eukaryotic cell division. It coordinates mitotic entry and progression by phosphorylating numerous targets and integrating signals from checkpoint pathways, interacting with cyclins and regulatory phosphatases. CDK1 activity is essential across taxa and is studied in contexts ranging from developmental biology to oncology.
CDK1 drives the G2–M transition and mitotic events through phosphorylation networks that link DNA replication status, spindle assembly, and checkpoint signaling. It integrates inputs from James Watson-era cell cycle models, Lee Hartwell-inspired checkpoint concepts, and molecular pathways elucidated by work in Saccharomyces cerevisiae, Schizosaccharomyces pombe, and vertebrate systems such as Xenopus laevis egg extracts and Mus musculus embryos. CDK1 activity is modulated by the ATM kinase and ATR kinase-mediated DNA damage response, the p53 pathway, and mitotic checkpoint forces at the spindle assembly checkpoint mediated by proteins like Mad2 and BubR1.
CDK1 adopts the cyclin-dependent kinase fold first characterized in studies of Protein kinase A and structural analyses involving groups at EMBL and Brookhaven National Laboratory. The kinase domain contains an ATP-binding pocket and activation segment whose conformation is controlled by regulatory phosphorylation at sites identified in biochemical work from laboratories such as Tony Hunter's. Regulatory inputs include binding partners like cyclins and modulators such as Wee1 kinase and Cdc25 phosphatase, whose activities are governed by upstream regulators including Chk1 and PP2A complexes characterized in studies at Cold Spring Harbor Laboratory.
CDK1 is activated by association with A- and B-type cyclins first mapped in genetic screens by researchers at Cold Spring Harbor Laboratory and in cell-free systems developed at Princeton University and Rockefeller University. Cyclin binding repositions the T-loop and permits phosphorylation by activating kinases and removal of inhibitory phosphates by Cdc25C phosphatase, a regulation influenced by MAPK signaling cascades and feedback loops described in work from Max Planck Institute groups. Negative regulation via Wee1 and activation via the Anaphase-promoting complex-mediated cyclin degradation create temporal patterns of CDK1 activity essential for mitotic exit, as revealed by studies at Harvard Medical School and MIT.
CDK1 phosphorylates a wide range of substrates controlling chromatin condensation, nuclear envelope breakdown, spindle dynamics, and cytokinesis. Substrate examples include components studied in landmark papers such as Histone H1, lamin proteins investigated by groups at UCSF, condensin complexes characterized at Max Planck Institute for Molecular Cell Biology and Genetics, kinetochore proteins including those examined at EMBL-EBI, and microtubule regulators studied at The Salk Institute. CDK1-mediated phosphorylation coordinates with ubiquitin ligases such as the SCF complex and APC/C to order proteolysis events, as described in work from Stanford University and Yale University.
CDK1-cyclin complexes display regulated localization patterns between nucleus, cytoplasm, centrosomes, and mitotic structures, an aspect explored in live-cell imaging studies at University of Cambridge and The Rockefeller University. Nuclear import/export signals and interactions with scaffolds like centrosomal proteins characterized at Cold Spring Harbor Laboratory determine spatial control, while phosphorylation cycles coordinate with centrosome maturation processes studied by teams at Johns Hopkins University and Institut Pasteur.
Aberrant CDK1 regulation impacts developmental programs and contributes to diseases including cancer, where dysregulated cell division was framed by clinical research at Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. CDK1's role in embryogenesis has been elucidated in Drosophila melanogaster and Caenorhabditis elegans genetic models developed at University of California, Berkeley and Washington University in St. Louis. Therapeutic interest stems from its centrality to proliferation, with links to oncogenes and tumor suppressors studied at Dana-Farber Cancer Institute and drug discovery efforts in pharmaceutical research at Novartis and Pfizer.
CDK1 function is probed using genetic knockouts, RNA interference pioneered at Cold Spring Harbor Laboratory, chemical-genetic analog-sensitive alleles developed in chemical biology groups at University of California, San Francisco, and in vitro kinase assays standardized at EMBL. Small-molecule inhibitors such as roscovitine, and selective compounds identified in screens at AstraZeneca and GlaxoSmithKline, are used to dissect CDK1-dependent processes and as leads in oncology trials conducted at National Cancer Institute and academic medical centers. Structural studies using X-ray crystallography and cryo-EM from consortia including HHMI and European Molecular Biology Laboratory have informed rational inhibitor design.
Category:Protein kinases Category:Cell cycle proteins